Gianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., . . . Semiglazov, V. (2013). AVEREL: A randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Journal of clinical oncology, 31(14), 1719. https://doi.org/10.1200/JCO.2012.44.7912
Citácia podle Chicago (17th ed.)Gianni, Luca, et al. "AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination with Docetaxel and Trastuzumab as First-line Therapy for HER2-positive Locally Recurrent/metastatic Breast Cancer." Journal of Clinical Oncology 31, no. 14 (2013): 1719. https://doi.org/10.1200/JCO.2012.44.7912.
Citácia podľa MLA (8th ed.)Gianni, Luca, et al. "AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination with Docetaxel and Trastuzumab as First-line Therapy for HER2-positive Locally Recurrent/metastatic Breast Cancer." Journal of Clinical Oncology, vol. 31, no. 14, 2013, p. 1719, https://doi.org/10.1200/JCO.2012.44.7912.